Baric Transcribed Interview (Redacted) — page 84

DC.Scheduling@LexitasLegal.com the reagents that they could use to develop countermeasures and vaccinate swine. The other issue, just to go on on that, you know, it's hard to imagine a better reservoir species for emerging virus than a swine. And the swine population, they have billions of swine in China, so you have this massive reservoir. And you have a virus that drops into those, and that virus can use, although not very well, it can use the human receptor for entry. MS. SALAZAR: So I've seen SADS come up a lot when people are talking about pan-corona vaccines. DR. BARIC: I wouldn't include it in a pan-corona vaccine because -- MS. SALAZAR: Am I mistaking it with PEDV? DR. BARIC: It's a lower probability virus. Okay. So for a pan-coronavirus vaccine you have pan-coronavirus beta coronavirus vaccines and alpha coronavirus vaccines. So this is an alpha coronavirus. So the only thing that people have really worked on extensively are pan-beta coronavirus vaccines, focused heavily on SARS coronavirus and MERS coronavirus. So I don't imagine that that would be included in any pan-beta coronavirus vaccine. Now, for pan-alpha coronavirus vaccines, the classic human coronaviruses are 229E and LN63. SADS would be something that you might want to consider. But the fact of